OBJECTIVES: There are only limited data on the survival outcomes after transplanting HCV RNA–positive liver into HCV RNA–negative recipients. The objective of our study was to determine whether there were graft and patient survival differences when HCV-negative patients received HCV RNA (nucleic acid amplification testing [NAT] positive)–positive liver grafts. METHODS: We queried the United Network for Organ Sharing data sets from January 2014 to December 2018, and recipients (N = 24,724) were stratified into 6 groups based on the status of HCV antibody and RNA of recipients and donors. The Cox proportional hazard regression was used to estimate the relationship between groups and 1-year post-LT graft or patient survival. RESULTS: During the study period, 1,358 recipients received NAT-positive liver grafts. Two hundred ten of the recipients were HCV negative. During the same period, 707 HCV antibody–positive but NAT-negative grafts were transplanted into 516 HCV-positive and 191 HCV-negative recipients. There were no differences in survival in HCV-positive recipients whether they received NAT-positive grafts (n = 1,148) or HCV antibody–negative/NAT-negative grafts (n = 6,321). Recipients of grafts from HCV antibody–positive/NAT-negative donors had similar survival whether recipients were HCV-negative patients (n = 191) or HCV-positive patients (n = 516), and their survival probabilities were similar to those of HCV-negative recipients (n = 6,321) receiving grafts from HCV antibody–negative/NAT-negative donors. Patient survival was lower (P = 0.049) when HCV-negative recipients (n = 210) received NAT-positive grafts compared with HCV-positive patients (n = 1,148) receiving NAT-positive grafts; however, when adjusted for recipient and donor characteristics, the difference was not significant. DISCUSSION: HCV-negative recipients receiving HCV-positive liver grafts (NAT positive) have excellent 1-year survival outcomes. Correspondence: Paul J. Thuluvath, MD, FRCP. E-mail: thuluvath@gmail.com. SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B460 Received November 26, 2019 Accepted February 03, 2020 © The American College of Gastroenterology 2020. All Rights Reserved.

中文翻译：

---

在 HCV 阴性受体中使用 HCV 阳性肝脏。

目的：关于将 HCV RNA 阳性肝脏移植到 HCV RNA 阴性受者体内后的生存结果数据有限。我们研究的目的是确定当 HCV 阴性患者接受 HCV RNA（核酸扩增测试 [NAT] 阳性）阳性肝移植物时，移植物和患者的生存率是否存在差异。方法：查询2014年1月至2018年12月器官共享联合网络数据集，根据受者和供者的HCV抗体和RNA状况将受者（N = 24,724）分为6组。Cox 比例风险回归用于估计组与 LT 移植后 1 年或患者生存率之间的关系。结果：在研究期间，1,358 名受者接受了 NAT 阳性肝移植。201 名接受者中的 HCV 呈阴性。同一时期，707 例 HCV 抗体阳性但 NAT 阴性的移植物被移植到 516 例 HCV 阳性和 191 例 HCV 阴性受者体内。无论 HCV 阳性受者接受 NAT 阳性移植物 (n = 1,148) 还是 HCV 抗体阴性/NAT 阴性移植物 (n = 6,321)，HCV 阳性受者的生存率均无差异。无论受者是 HCV 阴性患者 (n = 191) 还是 HCV 阳性患者 (n = 516)，来自 HCV 抗体阳性/NAT 阴性供体的移植物受者的存活率相似，并且他们的存活概率与 HCV 抗体相似。接受 HCV 抗体阴性/NAT 阴性供者移植物的阴性受者 (n = 6,321)。与接受 NAT 阳性移植物的 HCV 阳性患者 (n = 1,148) 相比，当 HCV 阴性受者 (n = 210) 接受 NAT 阳性移植物时，患者存活率较低 (P = 0.049)；然而，根据受赠者和捐献者的特征进行调整后，差异并不显着。讨论：接受 HCV 阳性肝移植（NAT 阳性）的 HCV 阴性受者具有优异的 1 年生存结果。通讯作者：Paul J. Thuluvath，医学博士、皇家内科医师学会会员。电子邮件：thuluvath@gmail.com。本文附带的补充材料位于 http://links.lww.com/AJG/B460 收稿日期：2019 年 11 月 26 日 接受日期：2020 年 2 月 3 日 © 美国胃肠病学会 2020。保留所有权利。